Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Kailera makes history with record-breaking $625m IPO

 April 17, 2026

Pharmaceutical Technology

Kailera’s IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials.

M&A / DealsRead full story

Post navigation

Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool →
← Trump signs order to hasten psychedelic medicine access

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com